TABLE 4

Potential therapeutic application of EP1 antagonists

EP1 AntagonistsRouteDoseSpeciesExperimental ModelIndicationReference
ONO-8711Intravenous1 and 3 mg/kgRatAcetic acid-induced inflammationBladder inflammationIkeda et al., 2006
ONO-8711Dietary400 or 800 ppmRatPhIP-induced breast cancerBreast cancerKawamori et al., 2001a,b
ONO-8711Dietary250, 500, 1000 ppmMouseAzoxymethane-induced aberrant crypt foci, Min miceColon cancerWatanabe et al., 1999
ONO-8713Oral20 mg/kgMouseDNFB contact sensitivityContact dermatitisNagamachi et al., 2007
ONO-8713Topical50 μgMouseUVB-induced inflammation and tumor formationSunburn, skin cancerTober et al., 2006
ONO-8713Dietary250, 500 1000 ppmMouseAzoxymethane-induced aberrant crypt fociColon cancerWatanabe et al., 2000
ONO-8713Intraventricular0–1–10 nMMouseNMDA excitotoxicityStrokeAhmad et al., 2006a
ONO-8713Intraperitoneal10 mg/kgMouseCerebral artery occlusionStrokeAhmad et al., 2006a
ONO-8713Intrathecal1 or 10 nmolMouseNeurochemical allodyniaPainTsukamoto et al., 2010
PF-2907617-02Intravenous1 mg/kgRatBalloon catheter-induced bladder outlet obstructionOveractive bladder syndromeLee et al., 2007a,b
SC-51089Intraperitoneal25 mg/kgMiceKMG4 tumor xenografts on SCID miceGliomaMatsuo et al., 2004
SC-51089Intraperitoneal10 mg/kgRatLithium-pilocarpine status epilepticusEpilepsyPekcec et al., 2009
SC-51322Oral10 mg/kgRatSpontaneously hypertensive ratHypertensionGuan et al., 2007
  • PhIP, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine; SC-51089, dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-(1-oxo-3-(4-pyridinyl)propyl)hydrazide, monohydrochloride.